Biosimilar approvals, pricing and market entry
mAbxience and Sandoz have signed a global collaboration agreement to develop and commercialize a biosimilar candidate of emicizumab, targeting the haemophilia A market valued at $5.7 billion.
Biosimilar approvals, pricing and market entry
mAbxience and Sandoz have signed a global collaboration agreement to develop and commercialize a biosimilar candidate of emicizumab, targeting the haemophilia A market valued at $5.7 billion.
Argentina’s Grupo Insud is building a biologics platform: mAbxience exports biosimilars across three continents while Sinergium anchors Latin America’s mRNA vaccine sovereignty.
You must be logged in to post a comment.